Hiltrud Beatrix Brauch

PERSONAL
Date of Birth: March 13, 1955
German citizen
Single

ACADEMIC DEGREES AND AWARDS

• University of Karlsruhe, Diploma in Chemistry, 1981
• University of Heidelberg, Institute of Immunology and Serology, PhD, 1985
• Fogarty International Visiting Fellowship, program of collaborative research experience in the United States (Oktober 1985-Januar 1989), The National Institutes of Health (NIH), U.S.A. 1985-1989
• Technical University Munich (TUM), Medical Faculty, Habilitation in Molecular Pathology, 1996
• University Hamburg: Member of the Medical Faculty, Venia Legendi in Molecular Biology, 1997
• University Tuebingen: Member of Medical Faculty: Venia Legendi in Molecular Pathology, 2000,
• University Tuebingen: “Außerplanmäßige” Professorin since 2006

EMPLOYMENT

• University of Heidelberg, Institute of Immunology and Serology, Research Assistant, 1981-1985
• Laboratory of Immunobiology (LIB)-National Cancer Institute (NCI)-Frederick Cancer Research and Development Cancer (FCRDC), Frederick Maryland USA, Visiting Fellow, 1985-1989
• LIB, PRI-Inc. NCI-FRCRDC, Scientist, 1989-1990
• German Cancer Research Center (DKFZ), Scientist, 1990-1992
• Institute of Pathology and Pathological Anatomy TUM, Section Head, Laboratory of Molecular Pathology, 1992-1996
• Womens Hospital Eppendorf, University of Hamburg, Head of Research Laboratory and Gynecological Diagnostics 1996-1999
• Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart, Section Head Molecular Mechanisms of Origin and Treatment of Breast Cancer, 1999 to 2008
• Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart, Deputy Head of the Institute and Section Head Breast Cancer Susceptibility and Pharmacogenomics since 2008

MAIN RESEARCH INTERESTS

• Breast Cancer Susceptibility
• Genetic polymorphisms and risk (GENICA Project)
• Gene environment interactions (GENICA Project)
• Hormone replacement - genome relationships (GENICA-MARIE Project)
  
  Molecular Mechanisms of Antihormonal and Chemotherapeutic Treatment in Breast Cancer
• Tamoxifen pharmacogenomics
• Genetic polymorphisms of drug response/non response
• Tumor bound factors of progression and metastasis as potential drug targets
  
  Breast Cancer Stem Cells
• Molecular characteristics and signaling pathways of breast cancer tumorigenesis
  
  Molecular Origin of Hereditary (VHL disease) and Sporadic Kidney Cancer
• VHL tumor suppressor gene and genetic risk factors
• Genotype - phenotype relationships
• Molecular origin of kidney cancer
• Kidney Cancer and Environment

LEAD APPLICANT AND COORDINATOR OF EU TRAINING SITE AND NETWORKS

• 5FP: Marie Curie Training Site Stuttgart/Tübingen: “Fighting Breast Cancer” (European PhD Training Programme 2001 to 2005)
• 7FP PEOPLE- Initial Training Network (ITN) FightingDrugFailure (2009-2013) COORDINATOR OF RESEARCH NETWORK
• The Interdisciplinary Study Group on Gene ENvironment Interactions and Breast CAncer in Germany (GENICA) for the identification of breast cancer susceptibility genes (funded by BMBF)

PARTICIPATION IN NATIONAL AND INTERNATIONAL RESEARCH NETWORKS

• Improvement of Breast Cancer Diagnosis and Treatment Tübingen-Stuttgart (funded by BMBF)
• MARIE-GENICA Consortium for the identification of constitutional factors predictive for the risk to develop breast cancer following hormone replacement therapy (MARIE: MAmmakarzinom RIsikofaktoren-Erhebung) (funded by BMBF)
• International Breast Cancer Association Consortium (BCAC) for the identification of breast cancer susceptibility genes
• International Tamoxifen Pharmacogenomics Consortium, member of the Steering Committtee

PUBLICATIONS

• More than 100 original articles, 6 invited articles and editorial, 5 reviews, 12 book chapters, more than 100 contributions to international meetings and more than 120 invited talks

TEACHING

• University of Heidelberg, Seminars in Immunology for doctoral students and post doctoral fellows
• University of Hamburg, Lectures: Basics in Molecular Biology and Molecular Origin of Breast Cancer
• University of Tuebingen, Lectures: Molecular Pathology in Diagnostics and Therapy of Organ Systems and Methods in Molecular Biology and Application in Clinical Research
• University of Tuebingen, Lectures: Hereditary and Sporadic Cancers
• Training and supervision of MD students during preparation of thesis
• Training and supervision of National and European PhD students (Marie Curie Mobility Program) Completion of 5 PhD and 2 Diploma theses
• Training of national and international research fellows

MEMBERSHIPS

• American Association of Cancer Research (AACR),
• AACR-Molecular Epidemiology Group (MEG),
• AACR-Women in Cancer Research (WICR)
• American Society of Human Genetics (ASHG)
• Gesellschaft für Biochemie und Molekularbiologie (GBM)
• Verein für von der von Hippel-Lindau (VHL) Erkrankung betroffene Familien e.V. (Board of Scientist of the VHL Family Alliance Germany)

REVIEWING ACTIVITIES WITH JOURNALS, FOUNDATIONS AND FUNDING AGENCIES

• Editorial Board of Pharmacogenetics and Genomics
• American Journal of Kidney Disease (AJKD)
• Anticancer Drugs
• Biomed Central Cancer
• Breast Cancer Research
• Clinical Cancer Research
• Cancer Letters
• Genes Chromosomes and Cancer
• Human Mutation (Hum Mutat)
• International Journal of Cancer
• Lancet Oncology
• Molecular Cancer
• Molecular and Cellular Probes (MCP)
• Pharmacogenomcis and Personalized Medicine
• Physiological Genomics
• Proceedings of the National Academy of Sciences (PNAS)
• Deutsche Krebshilfe (German Research Council)
• European Commission
• Foundation Emmanuel van der Schueren, Belgium
• Fonds zur Förderung der wissenschaftlichen Forschung, Austria
• Medical Research Council, United Kingdom
• Ministry of Health, Singapore
• Ohio Cancer Research Associates, USA
• Royal Adelaide Hospital, Australia
• United States-Israel Binational Science Foundation
• Wilhelm Sander Stiftung, Germany